Document is current
Any future updates will be listed below
-
Authors
Béraud, Guillaume
Mosnier, Anne
Guérin, Olivier
Cugnardey, Nathalie
Gillet, Sandrine
Haond, Justine
Simon, Stéphane
Berkovitch, Quentin https://orcid.org/0009-0007-3578-537X
Gamblin, Pierre
Lesage, Henri
Loubet, Paul
-
Funding
Funding for this research was provided by:
Viatris
- License Information
-
More Information
Article History
Received: 11 April 2025
Accepted: 13 May 2025
First Online: 8 June 2025
Declarations
:
: Stéphane Simon, Sandrine Gillet, Justine Haond and Nathalie Cugnardey are Viatris employees and may hold shares in the company. Paul Loubet has received payment or honoraria for lectures, presentations, speakers bureau, manuscript writing or educational events from Astrazeneca, GlaxoSmithKline, Janssen, Moderna, Merck Sharp & Dohme, Pfizer, Sanofi Pasteur, Seqirus. Anne Mosnier participated in Viatris, Sanofi and Seqirus Advisory Boards as part of being an Open Rome employee and without any individual benefit. Guillaume Béraud and Olivier Guérin participated in Viatris Advisory Boards. Quentin Berkovitch, Henri Lesage and Pierre Gamblin were contracted by Viatris to conduct this study.
: This cost-effectiveness model was conducted based on analyses of a secondary-use database and did not recruit any human participants or involve animals.
